TNXP vs. GALT, INZY, ABOS, ENTX, XFOR, CLLS, SCLX, TARA, IGMS, and ALGS
Should you be buying Tonix Pharmaceuticals stock or one of its competitors? The main competitors of Tonix Pharmaceuticals include Galectin Therapeutics (GALT), Inozyme Pharma (INZY), Acumen Pharmaceuticals (ABOS), Entera Bio (ENTX), X4 Pharmaceuticals (XFOR), Cellectis (CLLS), Scilex (SCLX), Protara Therapeutics (TARA), IGM Biosciences (IGMS), and Aligos Therapeutics (ALGS). These companies are all part of the "pharmaceutical products" industry.
Tonix Pharmaceuticals vs.
Galectin Therapeutics (NASDAQ:GALT) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, community ranking, institutional ownership and dividends.
Galectin Therapeutics has higher earnings, but lower revenue than Tonix Pharmaceuticals. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Galectin Therapeutics presently has a consensus target price of $11.00, suggesting a potential upside of 638.26%. Tonix Pharmaceuticals has a consensus target price of $5,350.00, suggesting a potential upside of 58,242.42%. Given Tonix Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Tonix Pharmaceuticals is more favorable than Galectin Therapeutics.
Galectin Therapeutics has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals has a beta of 2.07, indicating that its share price is 107% more volatile than the S&P 500.
Galectin Therapeutics received 7 more outperform votes than Tonix Pharmaceuticals when rated by MarketBeat users. However, 60.71% of users gave Tonix Pharmaceuticals an outperform vote while only 59.11% of users gave Galectin Therapeutics an outperform vote.
11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 50.1% of Galectin Therapeutics shares are owned by insiders. Comparatively, 0.0% of Tonix Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Galectin Therapeutics has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -1,197.86%. Galectin Therapeutics' return on equity of 0.00% beat Tonix Pharmaceuticals' return on equity.
In the previous week, Galectin Therapeutics had 2 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 2 mentions for Galectin Therapeutics and 0 mentions for Tonix Pharmaceuticals. Galectin Therapeutics' average media sentiment score of 0.20 beat Tonix Pharmaceuticals' score of 0.00 indicating that Galectin Therapeutics is being referred to more favorably in the media.
Summary
Tonix Pharmaceuticals beats Galectin Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Tonix Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tonix Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:TNXP) was last updated on 2/21/2025 by MarketBeat.com Staff
